Esketamine Combined Pulsed Radiofrequency for Acute/Subacute Zoster-associated Trigeminal Neuralgia
Effect of Intravenous Infusion of Esketamine Combined Pulsed Radiofrequency on Acute/Subacute Zoster-associated Trigeminal Neuralgia
Beijing Tiantan Hospital
174 participants
Apr 1, 2025
INTERVENTIONAL
Conditions
Summary
To assess the 1-month effects and safety of esketamine combined PRF and standardized treatment to relieve pain in patients with acute/subacute zoster-related trigeminal neuralgia(ZRTN).
Eligibility
Inclusion Criteria5
- Age \>18 years;
- History of HZ within the last three months;
- Lesions located in the trigeminal nerve or its branches innervated regions；
- Numeric Rating Scale (NRS) pain score≥4 (NRS, 0 = no pain, 10= worst possible pain) with pharmacotherapy;
- Planned to perform CT-guided PRF treatment of the Gasserian ganglion .
Exclusion Criteria15
- Obstructive sleep apnoea syndrome;
- Those who receive other invasive treatments, such as spinal cord stimulation;
- A history of systemic immune diseases, organ transplantation, or cancers;
- A history of severe cardiopulmonary, hepatic or renal dysfunction;
- A history of schizophrenia, epilepsy, or myasthenia gravis, delirium;
- Comorbid hyperthyroidism or phaeochromocytoma;
- Recent history of drug abuse;
- Having contraindications to esketamine;
- Communication difficulties.
- Withdrawal criteria
- Lost to follow-up during the study;
- Not perform the planned operation;
- Receiving other treatment regimes during the study period;
- Not suitable for continuing the study for emerging severe comorbidities or special physiological changes during the study;
- Voluntary withdrawal from the study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients in the esketamine group will receive intravenous infusion of esketamine besides PRF+standardized treatment.The formula will be intravenous infusion of 0.5mg/kg of esketamine diluted in 50 mL normal saline, starting with intravenous injection of 10 mg of esketamine for 1 minute, and maintaining a dose 8 mg/h.The infusion rate will be adjusted the parameter according to the tolerance of the patients
Patients in the control group will receive PRF+standardized treatment
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06890897